Deal notes
Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.
Transaction overview
01Yarrow Bioscience, Inc. disclosed a $172.5M underwritten public offering at $26.00 per share. Jefferies LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC, LifeSci Capital LLC participated in the financing.
- Financing type
- Underwritten Public Offering
- Announcement date
- —
- SEC disclosure date
- Sep 11, 2026
- Agreement date
- Sep 10, 2026
- Pricing date
- Sep 10, 2026
- Closing date
- —
- Filing date
- Sep 14, 2026
- Status
- Priced
- Market cap before SEC disclosure
- $24.4M
- Prior closing price
- $28.44
- Raise as % of market cap
- 706.9%
Market data · FMP
- Historical market cap
- $24,401,520
- Market date
- Sep 10, 2026
- Closing price
- $28.44
- Latest reported shares outstanding
- 17,196
- Latest reported float shares
- —
- Share-data date
- Sep 29, 2026
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.
Financial Modeling Prep ↗Financing terms
02Equity
- Common shares issued
- 6,634,615
- Price per share
- $26.00
- Pre-funded warrants
- —
- Pre-financing shares disclosed in filing
- —
- Shares outstanding after financing
- —
Fees & transaction economics
03- Placement agent / underwriting fee
- —
- Agent fee amount
- —
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- $161.8M
- Net proceeds as % of gross
- 93.8%
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Totals include the fully exercised 865,384-share option. Closing was still described as expected in the September 14 filing.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
172499990
to issue and sell 5,769,231 shares of the Company’s common stock at a public offering price of $26.00 per share (the “Offering”). In addition, the Company has granted the Underwriters an option (the “Option”) for a period of 30 days to purchase up to an additional 865,384 shares of its common stock at the public offering price, less the underwriting discounts and commissions, which the Underwriters exercised in full on September 11, 2026.Original source ↗
161800000
net proceeds from the Offering, including proceeds from the exercise in full of the Option by the Underwriters, are expected to be approximately $161.8 millionOriginal source ↗
6634615
to issue and sell 5,769,231 shares of the Company’s common stock at a public offering price of $26.00 per share (the “Offering”). In addition, the Company has granted the Underwriters an option (the “Option”) for a period of 30 days to purchase up to an additional 865,384 shares of its common stock at the public offering price, less the underwriting discounts and commissions, which the Underwriters exercised in full on September 11, 2026.Original source ↗
Totals include the fully exercised 865,384-share option. Closing was still described as expected in the September 14 filing.
to issue and sell 5,769,231 shares of the Company’s common stock at a public offering price of $26.00 per share (the “Offering”). In addition, the Company has granted the Underwriters an option (the “Option”) for a period of 30 days to purchase up to an additional 865,384 shares of its common stock at the public offering price, less the underwriting discounts and commissions, which the Underwriters exercised in full on September 11, 2026.Original source ↗
FMP reported market cap; as of 2026-09-10.
{"provider": "FMP", "symbol": "YARW", "date": "2026-09-10", "marketCap": 24401520}Original source ↗